Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes
- PMID: 19199166
- PMCID: PMC3140220
- DOI: 10.1080/00952990802585380
Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes
Abstract
Background: Despite evidence supporting the efficacy of buprenorphine relative to established detoxification agents such as clonidine, little research has examined: 1) how best to implement buprenorphine detoxification in outpatient settings; and 2) whether extending the length of buprenorphine detoxification improves treatment engagement and outcomes.
Objectives: The current study examined the impact on 1) successful detoxification completion; 2) transition to longer-term treatment; and 3) treatment engagement of two different length opioid detoxifications using buprenorphine.
Methods: The study compared data obtained from two consecutive studies of early treatment engagement strategies. In one study (n = 364), opioid-addicted participants entered treatment through a Brief (5-day) buprenorphine detoxification. In the other study (n = 146), participants entered treatment through an Extended (i.e., 30-day) buprenorphine detoxification.
Results: Results indicated a greater likelihood of successful completion and of transition among participants who received the Extended as compared to the Brief detoxification. Extended detoxification participants attended more counseling sessions and submitted fewer drug-positive urine specimens during the first 30 days of treatment, inclusive of detoxification, than did Brief detoxification participants.
Conclusions: Results demonstrate that longer periods of detoxification improve participant engagement in treatment and early treatment outcomes.
Scientific significance: Current findings demonstrate the feasibility of implementing an extended buprenorphine detoxification within a community-based treatment clinic.
Conflict of interest statement
All authors declare that they have no conflicts of interest.
Similar articles
-
Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction.Drug Alcohol Depend. 2011 Aug 1;117(1):24-30. doi: 10.1016/j.drugalcdep.2010.12.024. Epub 2011 Feb 1. Drug Alcohol Depend. 2011. PMID: 21277704 Free PMC article. Clinical Trial.
-
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.Am J Addict. 2004;13 Suppl 1(Suppl 1):S42-66. doi: 10.1080/10550490490440807. Am J Addict. 2004. PMID: 15204675 Free PMC article.
-
Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.JAMA. 2008 Nov 5;300(17):2003-11. doi: 10.1001/jama.2008.574. JAMA. 2008. PMID: 18984887 Free PMC article. Clinical Trial.
-
The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.Drug Alcohol Depend. 2011 Dec 1;119(1-2):1-9. doi: 10.1016/j.drugalcdep.2011.05.033. Epub 2011 Jul 8. Drug Alcohol Depend. 2011. PMID: 21741781 Free PMC article. Review.
-
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. doi: 10.3109/00952990.2011.653426. Epub 2012 Mar 12. Am J Drug Alcohol Abuse. 2012. PMID: 22404717 Free PMC article. Review.
Cited by
-
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.Addict Behav. 2012 Sep;37(9):1046-53. doi: 10.1016/j.addbeh.2012.04.011. Epub 2012 May 8. Addict Behav. 2012. PMID: 22626890 Free PMC article. Clinical Trial.
-
Outpatient-based buprenorphine-assisted opioid withdrawal management: A preliminary prospective observational study.Indian J Psychiatry. 2025 Apr;67(4):428-431. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_1084_24. Epub 2025 Apr 15. Indian J Psychiatry. 2025. PMID: 40371239 Free PMC article.
-
A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 10.1001/jamapsychiatry.2013.2216. JAMA Psychiatry. 2013. PMID: 24153411 Free PMC article. Clinical Trial.
-
On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.Drug Alcohol Depend. 2020 May 1;210:107958. doi: 10.1016/j.drugalcdep.2020.107958. Epub 2020 Mar 16. Drug Alcohol Depend. 2020. PMID: 32203863 Free PMC article.
-
Update on the clinical use of buprenorphine: in opioid-related disorders.Can Fam Physician. 2012 Jan;58(1):37-41. Can Fam Physician. 2012. PMID: 22267618 Free PMC article. Review.
References
-
- Substance Abuse and Mental Health Services Administration Office of Applied Studies. DASIS Series: S-40, DHHS Publication No. (SMA) 08-4313. Rockville, MD: 2008. Treatment Episode Data Set (TEDS) Highlights – 2006. National Admissions to Substance Abuse Treatment Services. Table 4.
-
- Becker A, Strain E, Bigelow G, Stitzer M, Johnson R. Gradual Dose Taper Following Chronic buprenorphine. The American Journal on Addictions. 2001;10:111–121. - PubMed
-
- Greenwald M, Schuh K, Stine S. Transferring Methadone-maintained outpatients to the buprenorphine sublingual tablet: A preliminary study. The American Journal on Addictions. 2003;12:365–374. - PubMed
-
- Bell J, Byron G, Gibson A, Morris A. A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug and Alcohol Review. 2004;23:311–317. - PubMed
-
- Collins E, Kleber H, Whittington R, Heitler N. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: A randomized trial. The Journal of the American Medical Association. 2005;294:903–913. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical